These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 10476886)

  • 1. Structure-activity relationship at the proximal phenyl group in a series of non-peptidyl N-type calcium channel antagonists.
    Ryder TR; Hu LY; Rafferty MF; Lotarski SM; Rock DM; Stoehr SJ; Taylor CP; Weber ML; Miljanich GP; Millerman E; Szoke BG
    Bioorg Med Chem Lett; 1999 Aug; 9(16):2453-8. PubMed ID: 10476886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of (2S)-1-(4-amino-2,3,5- trimethylphenoxy)-3-[4-[4-(4- fluorobenzyl)phenyl]-1-piperazinyl]-2-propanol dimethanesulfonate (SUN N8075): a dual Na(+) and Ca(2+) channel blocker with antioxidant activity.
    Annoura H; Nakanishi K; Toba T; Takemoto N; Imajo S; Miyajima A; Tamura-Horikawa Y; Tamura S
    J Med Chem; 2000 Sep; 43(18):3372-6. PubMed ID: 10978184
    [No Abstract]   [Full Text] [Related]  

  • 3. Synthesis of a series of 4-benzyloxyaniline analogues as neuronal N-type calcium channel blockers with improved anticonvulsant and analgesic properties.
    Hu LY; Ryder TR; Rafferty MF; Feng MR; Lotarski SM; Rock DM; Sinz M; Stoehr SJ; Taylor CP; Weber ML; Bowersox SS; Miljanich GP; Millerman E; Wang YX; Szoke BG
    J Med Chem; 1999 Oct; 42(20):4239-49. PubMed ID: 10514294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity relationship of N-methyl-N-aralkyl-peptidylamines as novel N-type calcium channel blockers.
    Hu LY; Ryder TR; Rafferty MF; Dooley DJ; Geer JJ; Lotarski SM; Miljanich GP; Millerman E; Rock DM; Stoehr SJ; Szoke BG; Taylor CP; Vartanian MG
    Bioorg Med Chem Lett; 1999 Aug; 9(15):2151-6. PubMed ID: 10465535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuronal N-type calcium channel blockers: a series of 4-piperidinylaniline analogs with analgesic activity.
    Hu LY; Ryder TR; Rafferty MF; Siebers KM; Malone T; Chatterjee A; Feng MR; Lotarski SM; Rock DM; Stoehr SJ; Taylor CP; Weber ML; Miljanich GP; Millerman E; Szoke BG
    Drug Des Discov; 2000; 17(1):85-93. PubMed ID: 10928451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N,N-dialkyl-dipeptidylamines as novel N-type calcium channel blockers.
    Hu LY; Ryder TR; Rafferty MF; Cody WL; Lotarski SM; Miljanich GP; Millerman E; Rock DM; Song Y; Stoehr SJ; Taylor CP; Weber ML; Szoke BG; Vartanian MG
    Bioorg Med Chem Lett; 1999 Mar; 9(6):907-12. PubMed ID: 10206559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity relationship at the leucine side chain in a series of N,N-dialkyldipeptidyl-amines as N-type calcium channel blockers.
    Ryder TR; Hu LY; Rafferty MF; Lotarski SM; Rock DM; Stoehr SJ; Taylor CP; Weber ML; Miljanich GP; Millerman E; Szoke BG
    Drug Des Discov; 2000; 16(4):317-22. PubMed ID: 10807036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The discovery of [1-(4-dimethylamino-benzyl)-piperidin-4-yl]-[4-(3,3-dimethylbutyl)-phen yl]-(3-methyl-but-2-enyl)-amine, an N-type Ca+2 channel blocker with oral activity for analgesia.
    Hu LY; Ryder TR; Rafferty MF; Taylor CP; Feng MR; Kuo BS; Lotarski SM; Miljanich GP; Millerman E; Siebers KM; Szoke BG
    Bioorg Med Chem; 2000 Jun; 8(6):1203-12. PubMed ID: 10896101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Voltage-sensitive calcium channel development in epileptic DBA/2J mice suggests altered presynaptic function.
    Esplin MS; Abbott JR; Smart ML; Burroughs AF; Frandsen TC; Litzinger MJ
    Epilepsia; 1994; 35(5):911-4. PubMed ID: 7925160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavioural and anticonvulsant effects of Ca2+ channel toxins in DBA/2 mice.
    Jackson HC; Scheideler MA
    Psychopharmacology (Berl); 1996 Jul; 126(1):85-90. PubMed ID: 8853221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity study and analgesic efficacy of amino acid derivatives as N-type calcium channel blockers.
    Seko T; Kato M; Kohno H; Ono S; Hashimura K; Takimizu H; Nakai K; Maegawa H; Katsube N; Toda M
    Bioorg Med Chem Lett; 2001 Aug; 11(16):2067-70. PubMed ID: 11514140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and biological evaluation of non-peptide analogues of omega-conotoxin MVIIA.
    Menzler S; Bikker JA; Suman-Chauhan N; Horwell DC
    Bioorg Med Chem Lett; 2000 Feb; 10(4):345-7. PubMed ID: 10714496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and evaluation of selective N-type calcium channel blockers: 6-unsubstituted-1,4-dihydropyridine-5-carboxylic acid derivatives.
    Yamamoto T; Niwa S; Tokumasu M; Onishi T; Ohno S; Hagihara M; Koganei H; Fujita S; Takeda T; Saitou Y; Iwayama S; Takahara A; Iwata S; Shoji M
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3639-42. PubMed ID: 22560585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation into the structure-activity relationship of novel concentration dependent, dual action T-type calcium channel agonists/antagonists.
    McCalmont WF; Patterson JR; Lindenmuth MA; Heady TN; Haverstick DM; Gray LS; Macdonald TL
    Bioorg Med Chem; 2005 Jun; 13(11):3821-39. PubMed ID: 15863008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antagonists of neuronal calcium channels: structure, function, and therapeutic implications.
    Miljanich GP; Ramachandran J
    Annu Rev Pharmacol Toxicol; 1995; 35():707-34. PubMed ID: 7598513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationships of omega-conotoxins at N-type voltage-sensitive calcium channels.
    Nielsen KJ; Schroeder T; Lewis R
    J Mol Recognit; 2000; 13(2):55-70. PubMed ID: 10822250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new omega-conotoxin that targets N-type voltage-sensitive calcium channels with unusual specificity.
    Favreau P; Gilles N; Lamthanh H; Bournaud R; Shimahara T; Bouet F; Laboute P; Letourneux Y; Ménez A; Molgó J; Le Gall F
    Biochemistry; 2001 Dec; 40(48):14567-75. PubMed ID: 11724570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct effects of mutations in transmembrane segment IVS6 on block of L-type calcium channels by structurally similar phenylalkylamines.
    Johnson BD; Hockerman GH; Scheuer T; Catterall WA
    Mol Pharmacol; 1996 Nov; 50(5):1388-400. PubMed ID: 8913371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and SAR of selective T-type calcium channel antagonists containing a biaryl sulfonamide core.
    Hangeland JJ; Cheney DL; Friends TJ; Swartz S; Levesque PC; Rich AJ; Sun L; Bridal TR; Adam LP; Normandin DE; Murugesan N; Ewing WR
    Bioorg Med Chem Lett; 2008 Jan; 18(2):474-8. PubMed ID: 18160281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro characterization of T-type calcium channel antagonist TTA-A2 and in vivo effects on arousal in mice.
    Kraus RL; Li Y; Gregan Y; Gotter AL; Uebele VN; Fox SV; Doran SM; Barrow JC; Yang ZQ; Reger TS; Koblan KS; Renger JJ
    J Pharmacol Exp Ther; 2010 Nov; 335(2):409-17. PubMed ID: 20682849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.